Although the mechanism of action has not been fully elucidated, the therapeutic effect of scoparone is to suppress inflammation and further improve NASH by inhibiting the PI3K/AKT/mTOR, ROS/P38/Nrf2 axis, and TLR4/NF-κB signaling pathway (Liu et al., 2019; Liu et al., 2020a). Here, NFKB1 is linked to metabolic dysfunction-associated steatohepatitis.